MWNA
EIDX

Marshall Wace North America’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Marshall Wace North America’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-183
Closed -$11K – 1742
2019
Q4 		$11K Buy
+183
New +$9.06K ﹤0.01% 1224
2018
Q3 		– Sell
-211,979
Closed -$4.31M – 1552
2018
Q2 		$4.31M Buy
+211,979
New +$4.44M 0.02% 554

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Marshall Wace North America's EIDX Position: Q1 2020 in Review

Marshall Wace North America sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2020, closing a stake of 183 shares — an estimated $11K sold.

Marshall Wace North America first reported a position in EIDX in Q2 2018 and held it in 2 quarters. The position peaked at $4.31M in Q2 2018. 89 funds tracked by Wall St. Rank hold EIDX as of Q1 2020.

  • Marshall Wace North America reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace North America sold 183 Eidos Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $11K.
  • Marshall Wace North America first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Marshall Wace North America's Eidos Therapeutics, Inc. Common Stock position peaked at $4.31M in Q2 2018.
  • 89 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.